$CDZI Financial News https://t.co/QtYJEAzPLW
Squeeze starts at $5.18 https://t.co/BRsstj5C4U
Funding agreement for evaluation of Mojave Groundwater Bank https://t.co/r2VvpXVHVW
Path to profitability https://t.co/fe7sd6UGVw
Declares quarterly dividend for Q1 2026 Series A https://t.co/H5nYlEf6e9
Selected to submit application for $194M WIFIA loan https://t.co/Z1KYYgUEiO
Investor update https://t.co/CtuXBZggTj
Q3 results https://t.co/CtuXBZggTj
B. Riley $15.00 PT https://t.co/767xQGfzSW
Roth/MKM $10.00 PT https://t.co/muO0DUMfwJ
$51M 1st tranche of up to $450M for Mojave Groundwater Bank project https://t.co/2GALm53uJn
Cadiz to provide perchlorate treatment to support Cactus Basins Recharge Program https://t.co/VIMZ0KZ3il
Signs 2nd MOU for hydrogen-solar development at Cadiz Ranch https://t.co/BgBZvMGU2b
Nation's largest tribal-led water project https://t.co/ucirQRP2fX
Highlighted in Los Angeles Business Journal https://t.co/McgatKSDqC
Twice the fresh water volume of Lake Mead https://t.co/VrBKMNlwFV
Deck https://t.co/pKxJ2WvfB3
Web https://t.co/rzQvO5MMRE
Publicity for this report paid for by third party.
@Cadiz_Inc Squeeze imminent. Future of water is clean and affordable. On clear path to profitability. Analysts forecast breakeven in 2 years, projected US$45M profit in 2028 with strong 59% avg annual growth. Delivering innovative water solutions. Links in thread
$GNPX Financial News https://t.co/lc5vZzzyls
Positive clinical data on biomarkets in patients receiving Reqorsa Gene Therapy https://t.co/IZILMwO466
Presents positive preclinical data on Type 2 diabetes gene therapy at ASGCT https://t.co/YPppQqkc7O
Patent granted https://t.co/EeElY8kkya
Presents positive preclinical data on Reqorsa gene therapy at AACR https://t.co/Xh8Q1E5rlL
To present positive pre-clinical data on Reqorsa gene therapy for lung cancer at AACR annual meeting https://t.co/dgzEQsXWaU
Reqorsa patent grants in Japan and Europe https://t.co/ShMEC1EibZ
Reverse split leaves only 9M shares issued. Low float and heavily shorted. Split adjusted data here https://t.co/iU4q9TwyYP
AI report identifies up to 30X undervaluation https://t.co/S0BKf22k5X
Positive preliminary preclinical data in Type 2 diabetic animal study of GPX-002 https://t.co/nolDYiuB4X
8-K filing shows Company believes it has the stockholder's equity from recent raises to meet NASDAQ mininmum listing requirements https://t.co/oTXo3jGE86
Adds clincial trial site for Acclaim-1 and Acclaim-3 lung cancer trials https://t.co/m7ZhkFh7gS
Acclaim-1 Phase 1 gene therapy clinical trial data published in Clinical Lung Cancer journal https://t.co/JJv8gKXnaw
Positive preclinical data on use of Reqorsa gene therapy for lung cancer https://t.co/xwbYb8NnjB
Patent issued for Requorsa combined with PD-L1 antibodies https://t.co/8wZ6FwZ6Up
European patent office intent to grant patent for combination of Reqorsa gene therapy and PD-1 antibodies https://t.co/pTywvfA03e
Deck https://t.co/8tFCXDlRvw
Web https://t.co/2oleEViKZw
Publicity for this report paid for by the Company.
@genprex Positive biomarker data published (Trop-2 H-scores 100+, PTEN scores below 100). Encouraging Type 2 diabetes gene therapy. Demonstrates in vivo proof-of-concept for novel diabetes gene therapy. Rejuvenated exhausted beta cells and normalized glucose levels. See links:
$WGRX Financial News https://t.co/C5rASVJYfr
Q1 results https://t.co/zRMWKUxSow
Accelerates digital health expansion https://t.co/ndznKX02wS
Pilot MSO collaboration with Kare PharmTech targeting $14B CCM and RPM services market https://t.co/G0bqMuDiPE
Joint venture with Kare PharmaTech https://t.co/cMLSi75PQ0
Shorts exposed https://t.co/sB69Cbj2V3
Report https://t.co/zefqrrL4ND
Squeeze starts at $0.61 https://t.co/uoI3BKI1Kj
Shareholder Letter https://t.co/sX0k2GJeav
Targets $70B market addressing muscle loss from weight loss therapies https://t.co/PBsusgOMiT
Fact Sheet https://t.co/u4LOxozqG4
Deck https://t.co/6xBaHsGS69
Web https://t.co/lcAZ8DhDvZ
Publicity for this report paid for by the Company.
@WGRX_Health Q1 revs near $1M with Q2 guidance of $1.77M . Expands direct sales with focus on $70B market for muscle loss from glp weight loss products. Kare joint venture expands access to 200,000+. EinsteinRx Ai platform optimizes dispensing and patient outcomes. Links below:
$RIME Financial News https://t.co/a8tZGT9LCo
Expanded contract with P&G India https://t.co/U2L5oUVGwh
Record Q1 results. Revs +71% from last quarter and +1,851% YOY https://t.co/zlLd4GMt5x
$12M annualized revenue run rate https://t.co/d392jl8xOx
45.65% of all trading volume is short selling. Squeeze starts at $1.99 https://t.co/AlVSV4Qvdu
SemiCab whitepaper https://t.co/LdOygG0vIx
Deck https://t.co/4ZbYzVMhcv
Web https://t.co/Vyogdxplzz
Publicity for this report paid for by the Company
@Algorhythm_AI Q1 results are off to a strong start with first quarter revenue growing more than 71% sequentially and more than 1,800% year-over-year as SemiCab business continues to scale. Apex SaaS platform positioned strong growth. Links in thread:
$NXXT Financial News https://t.co/6ZWE9ontYt
Q1 earnings call today at 9am EDT https://t.co/8X9n4uApG9
Q1 results. Revs +29% YOY to $21.1M, gross profit more than tripled and interest expense decreased by 80% YOY https://t.co/oSqehlzf5y
One of most promising renewable energy stories https://t.co/c2xPnPgyGd
Launches one of nation's largest last-mile mobile fuel delivery stations https://t.co/QPopPx9lZd
Ai-driven dashboard for integrated energy ecosystem https://t.co/jKocUpOPlD
Expands fleet in highest-margin markets and advances microgrid pipeline https://t.co/66Q3tMkPeT
Ai Deep Research Report with $6.30PT https://t.co/Z6gCV4YHW3
Simply Wallst report with $5.50PT https://t.co/Xyw631jlTl
48% of all trading volume shorted. Squeeze starts at $2.04 https://t.co/C6JZmsUoBV
NeutronX partnership focuses on federal energy and defense infrastructure projects https://t.co/ODda19pEMb
Microgrid operating model https://t.co/hl5macd0mU
Power generation, storage, electronics and software working together to power microgrids https://t.co/H7Hui2HrMq
Deck https://t.co/1xaUCZa4AV
Web https://t.co/uaj5QleX75
Publicity for this report paid for by the Company
@NextNRGinc Q1 results. $21.1M in revs, gross profit triples. Earnings call today at 9am EDT. Ai-powered microgrids respond to disruptions and offer autonomous distributed balanced generation while optimizing for cost and resilience. Links below:
$JSDA Financial News https://t.co/VZDqWQju3L
Q1 results. Revs $12.4M (+194% yoy), gross profit +179% to $3.9M. Raises 2026 full year revenue guidance to $40M+ https://t.co/A8CnM5wJU6
Expands product offerings in 650 top-volume stores nationwide https://t.co/AknaQkQlho
Expands Canadian distribution through 700 Circle K stores https://t.co/oj8S0vPOJF
Expands Fallout beverage platform with national club store rollout https://t.co/4xLARXK08j
Expanded Costco program increases Q4 momentum https://t.co/aEQj8vWexk
Squeeze starts at $0.74 https://t.co/4lCvndyNMp
Shorts exposed https://t.co/23AAbywroS
Report https://t.co/GfgJyv853M
Bolsters C-Suite with proven business leaders https://t.co/i3P8MgDP9G
Fallout-themed Vault-Tec Supply Packs at select Costco Warehouse Clubs https://t.co/uJAqrhqKkE
Expands in Southeast with additional Costco launch https://t.co/GAyOJ5VuXg
Web https://t.co/vWqgMOEps1
Publicity for this report paid for by the Company.
@jonessodaco Q1 results. Revs $12.4M (+194% yoy), gross profit +179% to $3.9M. Raises 2026 full year revenue guidance to $40M+. Expands Costco , CircleK and Walmart national and international distribution. Squeeze starts at $0.74. Links below:
$GTBP Financial News https://t.co/XCvjCQWJsF
Q1 results https://t.co/An1qB8PDOz
1st patient dosed in Phase 1 trial of GTB-5550, a B7-H2 targeted NK cell engage for solid tumors https://t.co/3CsvEy6Nwx
Full year 2025 results https://t.co/qIZtLiQAPe
FDA clearance of IND application for GTB-5550 https://t.co/r02MVlHNpG
Advances Phase I trials https://t.co/LPNDjCbabD
Q3 results https://t.co/mz3tOKNSTD
GTB-3650 advances Phase 1 trial to Cohort 4 following safety review of Cohort 3 https://t.co/STWDcmefX4
Reports progress in Phase 1 trial of lead candidate for blood cancers https://t.co/SJZQqFyYdi
Shorts exposed https://t.co/1R1mUlhUgw
Ai-powered Deep Research report $15.00 PT https://t.co/F5n5LvGztI
Roth/MKM $11.00 PT https://t.co/BTLrpqUhQO
Deck https://t.co/wr6NLcmEN8
Web https://t.co/XVywECRFpK
Publicity for this report paid for by the Company.
@GTBiopharma 1st human dosing. Advances 3 TriKE candidates. Platform combines precision, potency, and potential for fewer side effects than conventional treatments. GTB-3650 Phase 1 for AML/MDS hits Cohort 4 at 10µg/kg—no safety issues. Oncology market $139B-$268B by 2034. Links
$GTBP Financial News https://t.co/XCvjCQWJsF
1st patient dosed in Phase 1 trial of GTB-5550, a B7-H2 targeted NK cell engage for solid tumors https://t.co/3CsvEy6Nwx
Full year 2025 results https://t.co/qIZtLiQAPe
FDA clearance of IND application for GTB-5550 https://t.co/r02MVlHNpG
Advances Phase I trials https://t.co/LPNDjCbabD
Q3 results https://t.co/mz3tOKNSTD
GTB-3650 advances Phase 1 trial to Cohort 4 following safety review of Cohort 3 https://t.co/STWDcmefX4
Reports progress in Phase 1 trial of lead candidate for blood cancers https://t.co/SJZQqFyYdi
Shorts exposed https://t.co/WFh8xhHIoM
Ai-powered Deep Research report $15.00 PT https://t.co/F5n5LvGztI
Roth/MKM $11.00 PT https://t.co/BTLrpqUhQO
Deck https://t.co/wr6NLcmEN8
Web https://t.co/XVywECRFpK
Publicity for this report paid for by the Company.
@GTBiopharma $GTBP 1st human dosing. Advanced TriKE next-generation platform combines precision, potency, and potential for fewer side effects than conventional treatments. GTB-3650 Phase 1 for AML/MDS hits Cohort 4 at 10µg/kg—no safety issues. Oncology market $139B-$268B by 2034
$NXPL Financial News https://t.co/bGYQz8MiaE
$9.9 Million in Revenue for Q1 2026 with Record Quarterly Consolidated Gross Margins of 35% https://t.co/akYWEh0QzZ
Expects Q1 gross margins to jump to 34%+ https://t.co/j9ylQVkF4V
Regains full NASDAQ compliance https://t.co/7oKW3CUJ1N
Deploys PharmcoRX AI-powered presciption processing https://t.co/XzTiF0UQ18
$400k IoT contract brings military Q1'26 pipeline to $1.2M https://t.co/5UdweGPYu3
Full year earnings results https://t.co/Ph6W7r74wb
Launches 50 state nationwide fulfillment capabilities https://t.co/DJpdl1LjyA
$820,000 Global Telesat contract award https://t.co/2sXnnFLZsS
Expects $55M in 2025 revenues and higher margins in 2026 https://t.co/GzFcwoPMyL
Shorts exposed https://t.co/zdEW2bVFwb
Report https://t.co/bxxbFP1M2h
Squeeze starts at $13.52 https://t.co/PdZr0XVP5l
International expansion https://t.co/FW734B9WFH
Expands 5G and AI powered IOT through new Telit Cinterion agreement https://t.co/LWjNBVsWSG
Deck https://t.co/AwrlnDNIHk
Web https://t.co/mmtzSRqQ1s
Publicity for this report paid for by the Company.
@nextplat Q1 revs $9.9M with record 35% gross margins vs 21% in prior year. Reduces expenses 9%. Expects positive net income in 2nd half. $54.3M full year 2025 revs, 340B covered entities, higher margin fulfillment exceeding 6,000+ scripts per month. Links below:
$MBRX Financial News https://t.co/pE8CRb4ACN
MIRACLE Trial unblinding imminent as blinded data continues to significantly outperform historical benchmarks https://t.co/C3R6ISCsAn
Cleveland Clinic finds no clinically significant cardiotoxicity with Annamycin in R/R AML patients https://t.co/hFnZdTxdSE
Secures additional strategic patent https://t.co/1iaJzyvbxG
Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5
Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp
Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw
FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D
Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R
Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c
Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo
Shorts exposed https://t.co/wfr1PKBx5M
Deck https://t.co/C8eZhu7phl
Web https://t.co/EPK7T2Bnsx
Publicity for this report paid for by the Company.
@moleculinbio Trial unblinding imminent. ClevelandClinic finds no significant cardiotoxicity. Extends survival by more than 60% in metastatic pancreatic cancer pre-clin models. If mid '26 results of 45 person cohort confirms 40% CRc rate, risk drops. Links below:
$WGRX Financial News https://t.co/C5rASVKw4Z
Pilot MSO collaboration with Kare PharmTech targeting $14B CCM and RPM services market https://t.co/G0bqMuDQFc
Joint venture with Kare PharmaTech https://t.co/cMLSi76nFy
Shorts exposed https://t.co/sB69CbjAKB
Report https://t.co/zefqrrLCDb
Squeeze starts at $0.89 https://t.co/fVMXZGgIMa
LOI to potentially acquire Neuritek Therapeuics for $105M https://t.co/RvPtGOyJZq
Shareholder Letter https://t.co/sX0k2GJM03
Targets $70B market addressing muscle loss from weight loss therapies https://t.co/PBsusgPk8r
Fact Sheet https://t.co/u4LOxozYvC
Deck https://t.co/6xBaHsHpVH
Web https://t.co/lcAZ8Diblx
Publicity for this report paid for by the Company.
@WGRX_Health Targets $14B market with new collab. Kare joint venture expands access to 200,000+. $105M letter of intent to acquire Neuritek. Targets $70B market for muscle loss due to weight loss products. EinsteinRx Ai platform to optimize dispensing and patient outcomes. Links
$MBRX Financial News https://t.co/pE8CRb4ACN
MIRACLE Trial unblinding imminent as blinded data continues to significantly outperform historical benchmarks https://t.co/C3R6ISCsAn
Cleveland Clinic finds no clinically significant cardiotoxicity with Annamycin in R/R AML patients https://t.co/hFnZdTxdSE
Secures additional strategic patent https://t.co/1iaJzyvbxG
Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5
Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp
Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw
FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D
Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R
Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c
Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo
Shorts exposed https://t.co/IgXIFrtolr
Deck https://t.co/C8eZhu7phl
Web https://t.co/EPK7T2Bnsx
Publicity for this report paid for by the Company.
@moleculinbio Trial unblinding imminent. @ClevelandClinic finds no significant cardiotoxicity. Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models. If mid '26 results of 45-patient cohort confirms 40% CRc rate, clinical risk drops.
$MBRX Financial News https://t.co/pE8CRb4ACN
Secures additional strategic patent https://t.co/1iaJzyvbxG
Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5
Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp
Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw
FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D
Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R
Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c
Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo
Shorts exposed https://t.co/IgXIFrtolr
Deck https://t.co/C8eZhu7phl
Web https://t.co/EPK7T2Bnsx
Publicity for this report paid for by the Company.
@moleculinbio $MBRX Financial News https://t.co/pE8CRb4ACN
Secures additional strategic patent https://t.co/1iaJzyvbxG
Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5
Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp
Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw
FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D
Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R
Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c
Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo
Shorts exposed https://t.co/IgXIFrtolr
Deck https://t.co/C8eZhu7phl
Web https://t.co/EPK7T2Bnsx
Publicity for this report paid for by the Company.
@moleculinbio $MBRX Financial News https://t.co/pE8CRb4ACN
Secures additional strategic patent https://t.co/1iaJzyvbxG
Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5
Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp
Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw
FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D
Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R
Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c
Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo
Shorts exposed https://t.co/IgXIFrtolr
Deck https://t.co/C8eZhu7phl
Web https://t.co/EPK7T2Bnsx
Publicity for this report paid for by the Company.
$MBRX Financial News https://t.co/pE8CRb4ACN
Secures additional strategic patent https://t.co/1iaJzyvbxG
Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5
Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp
Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw
FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D
Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R
Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c
Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo
Shorts exposed https://t.co/IgXIFrtolr
Deck https://t.co/C8eZhu7phl
Web https://t.co/EPK7T2Bnsx
Publicity for this report paid for by the Company.
$MBRX Financial News https://t.co/pE8CRb4ACN
Secures additional strategic patent https://t.co/1iaJzyvbxG
Annamycin extends survival by more than 60% in metastatic pancreatic cancer preclinical models https://t.co/fhMU4qYKR5
Ai powered Deep Research Report shows potential valuation upside https://t.co/bANtjJQUpp
Hits enrollment milestone triggering countdown to mid-2026 trail data readout https://t.co/KvAVBs0Ylw
FY 2025 results and confirmation of mid-2026 interim data release https://t.co/cMYeAOVB2D
Trial delivers 40% preliminary blinded CRc rate (n=30) https://t.co/w0ba4oni7R
Patent allowance in Japan for Annamycin https://t.co/I4nLuq1u8c
Independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects https://t.co/45OfSLOqMo
Shorts exposed https://t.co/IgXIFrtolr
Deck https://t.co/C8eZhu7phl
Web https://t.co/EPK7T2Bnsx
Publicity for this report paid for by the Company.
Secures additional strategic patent. Annamycin extends survival by more than 60% in metastatic pancreatic cancer models. If mid '26 unblinding of 45-person cohort confirms 40% CRc rate, risk drops. Links below:
$CRDL Financial News https://t.co/oeVyN1Wixn
Phase 2 Maveric results accepted for publication in Journal of American Heart Association https://t.co/7c7nDkW7cW
Expands MAVERIC Phase III trial in the US https://t.co/LGLvDBwGre
CardiolRx shows Myocarditis promise https://t.co/hDBaQylEKg
Squeeze starts at $1.39 https://t.co/mGXiiAy4iY
Canaccord $8.00 PT https://t.co/LTfaaMauNM
FY 2025 results https://t.co/QPmHnbxRqT
ARCHER Phase 2 study results published in ESC Heart Failure https://t.co/5Y6YIqg1x2
50% enrollment in Phase 3 MAVERIC trial in recurrent pericarditis https://t.co/qC5rmOELNL
Leede $11.00PT https://t.co/iN5Hd1CuV2
Roth $10.00PT https://t.co/OJPQwlWd84
HC Wainwright $9.00PT https://t.co/jyf2M5w5H8
Deck https://t.co/jqJxbxLEi2
Web https://t.co/LWdxchpieP
Publicity for this report paid for by the Company.
@CardiolRx Phase 2 Maveric results accepted for publication in JAHA. Expands Phase 3 trial network. Positive Phase 2 Archer data in acute myocarditis. Advances CRD-38 program, a novel next generation therapy intended for use in heart failure. Broad patents. See links
$AMZE Financial News https://t.co/u0o0bznYRX
Partners with All Media Solutions to power brand supply for Amaze Live https://t.co/A5FhmqoyFR
LOI with Digital Innovations to integrate IRMA engine to expand creator and fan monetization https://t.co/dSTHGbKWTv
20 brands commit inventory to Amaze Live shopping https://t.co/QFIjYVwjMk
Launches next-generation multi-channel live shopping platform https://t.co/GXqMFIUGln
Get early access to Amaze Live shopping https://t.co/NUCZJq35hg
Launches Creator Commerce media platform https://t.co/17zlqe2T7D
Previews new product launch of Amaze Commerce https://t.co/mzJ4C81HLH
Shareholder update https://t.co/bbCcYIF82A
Amaze and LA Times Studios launch Food Channel LA, a creator-led commerce platform https://t.co/g5ZcsViyd5
Shorts exposed https://t.co/SowmjOJBNk
Report https://t.co/rQ0yWRi9Mk
Ladenburg Thalmann $3.00PT https://t.co/clBL063HXI
Squeeze starts at $1.04 https://t.co/C76j7UTdWt
Investor Summit presentation March 25th 9am EDT https://t.co/XLOx7oMIbJ
Expanded live shopping capabilities for creators https://t.co/EkBAHzyyb7
Launches proprietary programmtic advertising platform https://t.co/Tx1A16Xplz
Partners with https://t.co/74gsEWexXs to provide customizable Plushies for creators https://t.co/iF3RsXAJJe
Deck https://t.co/MgUj5JUYCO
Web https://t.co/m5PD9Vxfu8
Publicity for this report paid for by the Company.
Amaze partners with All Media Solutions for live shopping. Announces Creator Commerce media platform. Billions of visits and millions of stores, data has become key value creator. Launches creator-led Food Channel commerce platform with @LATimes. Links below:
THREAD
$XXII Financial News https://t.co/gVENVi0B1i
2026 vision for VLN product growth https://t.co/i7I45BQ3VT
New testing services agreement https://t.co/xLfh3SZamr
Targets half of $82B US market with 100mm VLN product initiative https://t.co/vdW1xHKxoN
Q4 results https://t.co/WPolZztgif
Shorts exposed https://t.co/sOx5omLA3i
Only combustible product authorized by FDA to specifically address cessation https://t.co/z4IHbksLZL
Emerging Growth issues updated report https://t.co/0cvAUKmnRZ
Emerging Growth report $9.00PT https://t.co/HCc2rEYcUF
Secures $9.5 million in proceeds from insurance claim settlement https://t.co/0tWaAn2uaD
Debt free balance sheet and new growth capital https://t.co/W5RDYzFjsj
Growing list of state authorizations https://t.co/RMd963V9Cl
Multiple brands partner to expand availability and awareness of VLN products https://t.co/y7deO9JZiw
Deck https://t.co/VG9aSW6dfR
Publicity for this report paid for by the Company.
@_xxiicentury Corporate update outlines vision for low nic alternative. Multiple scientific studies demonstrate merits of products. Non-addictive alternative in the fight against the harms of inhaled combustibles. Links in thread: